Information Provided By:
Fly News Breaks for November 13, 2019
Nov 13, 2019 | 05:27 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target for Marker Therapeutics to $6 from $10 after the FDA requested additional information on the technical specifications for two reagents used in manufacturing process and placed a clinical hold on the company's Investigational New Drug application. The analyst notes that these reagents are not present in the final MultiTAA product and that he ultimately expects the IND to be cleared. He reiterates an Overweight rating on the shares.
News For MRKR From the Last 2 Days
There are no results for your query MRKR